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Leading article
Clinical relevance of hepatitis C virus genotypes
Genotypes ofHCV
Hepatitis C virus (HCV) has been identified as the main
causative agent of post-transfusion non-A, non-B hepa-
titis.' 2 Infection with HCV is normally persistent (>20-30
years) and is associated with the development of chronic
active hepatitis and cirrhosis. Hepatic failure from
advanced liver disease is a frequent indication for liver
transplantation. In most countries, HCV has become one
of the principal identifiable causes of hepatocellular
carcinoma (HCC).
It is possible to classify HCV into a series of distinct
genotypes that differ substantially in nucleotide sequence
from one another and show varied geographical and
epidemiological distributions. Comparisons of complete
genome sequences, or of subgenomic regions such as El,
NS4 or NS5, have allowed variants to be classified into at
least six major genotypes, each of which comprises a
number of more closely related subtypes.' Variability is
distributed throughout the genome, with the non-
structural genes of different genotypes showing only
65-70% nucleotide sequence similarity. Genotypes 1, 2
and 3 are widely distributed throughout Western countries
and the Far East (Japan, China, Taiwan, Thailand),
whereas others show more restricted geographical distri-
butions. For example, types 5 and 6 are largely confined
to South Africa and South East Asia, respectively, whereas
type 4 is found predominantly in the Middle East and
in Central Africa. The underlying reasons for the
geographical differences in genotype distributions are
poorly understood; HCV is only efficiently transmitted
by parenteral routes, yet blood transfusion and needle-
sharing amongst drug misusers are historically relatively
recent innovations. Although recent analyses indicate
that the current genotypes of HCV evolved from a
common ancestor at least 500-2000 years ago,7 we have
little insight into the mechanism of HCV transmission
over this period. This century, successive waves of HCV
infection have occurred in many parts of the world,
including Europe, USA and the Far East, in association
with new risk groups for infection. This recent spread
of HCV was initially associated with types 2 and lb,
followed more recently by types la and 3a, the latter
being most frequently found in intravenous drug
misusers.7 12 As a result, the prevalence of HCV infection
has greatly increased over the past 50 years in most
countries, but only now are we beginning to realise the
medical consequences of this extremely slowly progressive
disease. '3
Serological diagnosis ofHCV infection
Laboratory diagnosis of HCV infection is most frequently
based upon the detection of antibody to HCV by ELISA.
Screening of blood donations has led to a great reduction
in the incidence of post-transfusion hepatitis caused by
HCV. However, serological tests are necessarily indirect,
and produce false negative results in acutely infected
individuals before seroconversion to antibody. Trans-
mission ofHCV through blood donations collected during
this relatively long "window" period remains a problem,
particularly for donations, collected from high risk
populations and from new donors. Although serological
assays for HCV have improved since their introduction in
1991, problems remain with their sensitivity and the lack
of adequate confirmatory tests for reactive specimens. For
example, current "confirmation" assays generally use the
same antigens as those present in the screening assay.
One question that has not been adequately addressed is
whether it is appropriate to screen individuals using
ELISAs based upon recombinant proteins derived from
only one genotype of HCV (almost invariably type a).
Significant antigenic variation between genotypes might be
expected to render current assays suboptimal for screening
patient and blood donor populations who may be infected
with variants other than type 1. At present, the extent to
which this leads to samples being missed from this cause
is unknown. Among the components of current second
and third generation screening assays, antigenic variation
is greatest in the non-structural proteins, such as c33c
(NS3), clOO (NS4) and NS5 (NS5a).8 14 In contrast, the
core protein amino acid sequence is highly conserved, and
it is likely that this component is the most effective at
detecting cross-reactivity with antibody produced to other
genotypes.8 To estimate the genotype dependence of the
sensitivity of the Ortho third generation assay, we
compared antibody reactivity of samples collected from
blood donors infected with genotypes 1, 2 and 3. Although
antibody titres varied greatly between individuals, we
found an approximate fivefold reduction in median
reactivity of type 2 and 3 samples in the ELISA,'5 a
difference in sensitivity that can be shown experimentally
to reduce substantially the number of samples that can be
detected on screening (Neville et al, unpublished data). As
a result of these findings, we are currently developing
ELISAs based upon recombinant proteins from other
genotypes, and comparing their effectiveness with con-
ventional assays for the screening of blood donors from
populations infected with variants other than type 1.
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Vaccine development
The degree of sequence variation between genotypes of
HCV is similar to that observed between variants of other
viruses, such as the four serotypes of the flavivirus, dengue
virus, or between poliovirus types 1, 2 and 3. Through the
use of in vitro neutralisation assays, it has been established
that an antibody response to one serotype does not protect
or neutralise the infectivity of another. Consequently, fully
protective vaccines for dengue and polio are multivalent
and contain antigens or attenuated virus strains of each of
the serotypes. Although there is no comparable neutral-
isation assay for HCV, it would be reasonable to assume
that antigenic variation, particularly in the envelope
proteins, El and E2, will have a significant effect upon
cross-neutralisation, and it is likely that an effective vaccine
for HCV would also have to contain immunogens from
each of the major genotypes.
Currently, a vaccine for HCV remains a distant
prospect; however, a weak and transient serological
response to recombinant envelope proteins can be elicited
by immunisation of chimpanzees, which has been shown
to protect or modulate infection from challenge with low
doses of the homologous virus strain.'6 In the future, a
number of issues need to be tackled, of which the most
important is whether a vaccine should be designed to
produce a predominantly neutralising antibody response
(the current strategy) or whether antigens should be
chosen to provoke cytotoxic T cell (CTL) activity. CTL
responses have been identified as the principal mechanism
for protective immunity from infection with simian
immunodeficiency virus, a model used for the de-
velopment of a vaccine to HIV-1. A comparable vaccine
for HCV containing proteins or peptides corresponding to
highly conserved T cell epitopes in the core and NS3
regions might induce a more broadly cross-protective
response than a vaccine based upon envelope proteins.
Disease progression
For most RNA viruses, the existence of extensive sequence
differences between serotypes has remarkably little effect
on the phenotype of a virus, other than in its antigenic
properties (see earlier). For example, poliovirus types 1, 2
and 3 seem to be equally infectious and equally likely to
cause paralytic disease by spread into the nervous system.
Similarly, different serotypes of dengue virus show similar
propensities to cause viral haemorrhagic fever. On the basis
of these and observations of other RNA viruses, there
would be no logical reason to suspect the existence of
major differences between genotypes of HCV in their
clinical course or disease associations.
This issue has been extensively investigated, mainly
taking the form of cross-sectional studies where the fre-
quencies of infection with different genotypes are com-
pared among patients with different disease outcomes,
such as the development of cirrhosis, HCC and auto-
immune disease - for example, mixed essential cryo-
globulinaemia. These studies have frequently produced
conflicting results; five major studies published since 1994
concluded that type lb was no more likely to cause
cirrhosis than other genotypes,"1 12 17-19 whereas six simi-
larly conducted investigations found a significantly greater
proportion of type lb infection among cirrhotic
patients.8 2024 These and other comparisons have found
increased alanine aminotransferase (ALT) levels in
patients infected with type lb compared with type 2 HCV,
although this was not necessarily associated with more
severe disease on examination of biopsy specimens.2>27
However, these investigations may have been affected by
different epidemiological characteristics of infection with
different genotypes that cannot be adequately corrected for
using multivariate analysis. For example, it could be
argued that the higher frequency of cirrhosis in type 1
infected individuals results from a longer mean duration
of infection than other genotypes. For this reason, disease
associations of type 3 are particularly difficult to compare
because of its association with intravenous drug misuse
and infection in a younger age group.8'2 However, people
infected with type lb and type 2 HCV in Japan have been
consistently shown to have similar age distributions and
risk factors yet often differ in stage of liver disease.28-30
There is a greater consensus that infection with type lb
predisposes towards the development of HCC,23 31-34 with
only two negative or contrary reports where significant
numbers have been analysed.30 35 There are also several
reports that liver transplantation of type lb infected
patients is associated with a higher rate of active disease
after transplantation and graft destruction.3*38 On the
basis of current knowledge, it is still difficult to conclude
whether type lb (or type 1 generally) has a greater patho-
genic potential than other genotypes, Unfortunately,
controlled prospective investigation of disease progression
among patients with known durations of infection is
hampered by the extremely slow course of disease.
Treatment
Alpha or lymphoblastoid interferon has been investigated
extensively as a treatment for HCV infection. In the past,
response to treatment was generally assessed by sustained
normalisation of ALT levels and improvement in liver
histology after treatment. More recently, PCR has been
used to monitor the disappearance of viraemia. Generally,
these measures of outcome are concordant. Based upon
the results of 40 published studies, representing the
collective experience of treating at least 3540 patients,
significant differences in response rates between genotypes
have been observed in 37. In a typical study,38a sustained
normalisation of ALT/clearance of viraemia was achieved
in only 11% of type 1 infected patients compared with
response rates of 60 and 33% for types 2 and 3. Higher
rates of response, particularly among those infected with
type 1, have been achieved by high dose interferon
administration (for example, 6 megaunits three times a
week for 12 months),39 40 or combination with riba-
virin.442 Other variables that independently increase re-
sponse rates are the absence of cirrhosis and low levels of
circulating virus RNA.
Little is currently understood about the underlying
mechanism for the observed differences in response rate.
This difficulty is compounded by our current ignorance of
the mechanism of action of interferon against HCV. Some
experimental observations suggest a direct antiviral action,
whereas others suggest that interferon is principally im-
munomodulatory and stimulates the immune system to
clear the virus, as is the case for hepatitis B virus. It has
been suggested that type lb has a greater replicative
capacity than other genotypes, possibly as a consequence
of genetic differences in a region of NS5a that acts as a
co-factor for RNA replication.43 44 Consistent with this
hypothesis, there are numerous reports (at least 14) that
type lb infection is associated with higher circulating virus
loads than type 2 (or type 3). However, studies using assays
that are equally sensitive for virus RNA of different geno-
types (for example, version 2 of the Chiron branched DNA
assay), or by correction ofvalues frombDNA version 1.0,4"
it has been shown consistently that virus loads among geno-
types 1 to 6 are similar." 46 46a These more recent findings
have the necessary implication that virus load and genotype
are independent predictors for response to interferon.
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Pre-treatment assessment of these variables will un-
doubtedly permit more appropriate patient selection for
treatment, or be used to calculate the necessary dose and
duration to obtain a sustained response. For example, a
recent Norwegian study, that assessed virus load, liver
biopsy appearance and genotype before treatment, identi-
fied a group of patients with a probability of response of
83% (type 2, virus load 105 copies RNA/ml) to standard
interferon treatment and another group with an 8% prob-
ability of response (type 1, virus load 3 X 1O copies RNA/
ml).12 In the future, pre-treatment variables such as virus
genotype should be incorporated into cost-benefit analyses
of HCV treatment to assist in the development of policies
for more effective management ofHCV infection.47
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